放射治疗与化学治疗与癌症患者主动脉瘤生长改变相关:同步癌症与主动脉瘤的影响
该单中心回顾性分析纳入2003至2020年217例同时患有腹主动脉瘤与癌症的患者,比较接受化疗或放疗者的动脉瘤生长速度与非癌症对照队列及荟萃分析数据。癌症与非癌症患者腹主动脉瘤年生长速度无统计学显著差异,但放疗与动脉瘤生长速度降低相关,抗代谢药与生长速度增加相关。
要点
- 癌症与非癌症患者腹主动脉瘤年生长速度无统计学显著差异。
- 放疗与癌症患者动脉瘤生长速度降低相关。
- 抗代谢药治疗与腹主动脉瘤生长速度增加相关。
核心结论
- 同时患有癌症与主动脉瘤的患者在接受特定治疗(如抗代谢药治疗)时可能需要加强监测,因其动脉瘤生长速度可能增加;放疗可能与动脉瘤生长速度降低相关。
研究设计与样本
- 回顾性单中心分析,纳入2003至2020年217例同时患有腹主动脉瘤与癌症的患者,共246个动脉瘤(58.8%为腹主动脉瘤)和238个恶性肿瘤;纳入标准为至少6个月内两次或以上CT血管造影并有额外恶性肿瘤。
- 将癌症治疗(化疗或放疗)下的腹主动脉瘤生长与非癌症腹主动脉瘤对照队列及荟萃分析数据进行比较;统计采用t检验和线性回归模型,校正初始主动脉直径和治疗类型。
主要发现
- 癌症与非癌症患者腹主动脉瘤年生长速度(均值±标准差)无统计学显著差异(2.0±2.3 vs. 2.8±2.1 mm/年;p=.20)。
- 放疗与癌症患者中未放疗者相比,平均动脉瘤生长速度统计学显著降低(1.1±1.3 vs. 1.6±2.1 mm/年;p=.046)。
- 放疗与非癌症对照队列相比,平均动脉瘤生长速度统计学显著降低(1.7±1.9 vs. 2.8±2.1 mm/年;p=.007)。
- 抗代谢药治疗导致腹主动脉瘤生长统计学显著增加(+0.9 mm/年;p=.011),拓扑异构酶抑制剂(-0.8 mm/年;p=.17)和抗雄激素(-0.5 mm/年;p=.27)显示生长降低的可能趋势。
- 髂动脉瘤(n=85)观察到相似结果;化疗联合方案(每患者2.6±1.4种药物)效应持续存在。
临床怎么用
- 同时患有癌症与主动脉瘤的患者在接受抗代谢药等特定治疗时可能需要加强监测,因动脉瘤生长速度可能增加;放疗可能与动脉瘤生长速度降低相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The purpose of this study was to assess the associations between malignancy, therapeutic regimens, and aorto-iliac aneurysm (i.e., abdominal aortic aneurysm [AAA]) growth rates. METHODS: A retrospective single centre analysis identified patients with an AAA plus cancer. Patients who had two or more computed tomography angiograms over six months or more and additional malignancy were included. Clinical data and aneurysm diameters were analysed. AAA growth under cancer therapy (chemotherapy or radiation) was compared with a non-cancer AAA control cohort and to meta-analysis data. Statistics included t tests and a linear regression model with correction for initial aortic diameter and type of treatment. RESULTS: From 2003 to 2020, 217 patients (median age 70 years; 92% male) with 246 aneurysms (58.8% AAA) and 238 malignancies were identified. Prostate (26.7%) and lung (15.7%) cancer were most frequently seen. One hundred and fifty-seven patients (72.3%) received chemotherapy, 105 patients (48.4%) radiation, and 79 (36.4%) both. Annual AAA growth (mean ± standard deviation) was not statistically significantly different for cancer and non-cancer patients (2.0 ± 2.3 vs. 2.8 ± 2.1 mm/year; p = .20). However, subgroup analyses revealed that radiation was associated with a statistically significantly reduced mean aneurysm growth rate compared with cancer patients without radiation (1.1 ± 1.3 vs. 1.6 ± 2.1 mm/year; p = .046) and to the non-cancer control cohort (1.7 ± 1.9 vs. 2.8 ± 2.1 mm/year; p = .007). Administration of antimetabolites resulted in statistically significantly increased AAA growth (+ 0.9 mm/year; p = .011), while topoisomerase inhibitors (- 0.8 mm/year; p = .17) and anti-androgens (- 0.5 mm/year; p = .27) showed a possible trend for reduced growth. Similar observations were noted for iliac aneurysms (n = 85). Additionally, the effects persisted for chemotherapy combinations (2.6 ± 1.4 substances/patient). CONCLUSION: Patients with cancer and concomitant aortic aneurysms may require intensified monitoring when undergoing specific therapies, such as antimetabolite treatment, as they may experience an increased aneurysm growth rate. Radiation may be associated with reduced aneurysm growth.
引用
- Becker von Rose A, Kobus K, Bohmann B, et al. Radiation and Chemotherapy are Associated with Altered Aortic Aneurysm Growth in Patients with Cancer: Impact of Synchronous Cancer and Aortic Aneurysm. Eur J Vasc Endovasc Surg. 2022. PMID: 35853577. doi:10.1016/j.ejvs.2022.07.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。